GU Cancers 2019 | Impact of prior therapy on enzalutamide in nmCRPC: post-hoc analysis of PROSPER
The PROSPER study (NCT02003924) is a Phase III, randomized trial of enzalutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC). The primary analysis of the study confirmed a clinically significant improvement in metastasis-free survival (MFS) in nmCRPC patients with the agent being trialled. Here, Ugo De Giorgi, MD, PhD, of the IRCCS, Meldola, Italy, discusses results from the post-hoc analysis of the study by prior therapy. This video was recorded at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA.
Get great new content delivered to your inboxSign up